DME treatment gets the German green light

Article

Chronic diabetic macula oedema (DME) treatment Iluvien, developed by Alimera Sciences, has obtained marketing authorization in Germany.

Chronic diabetic macula oedema (DME) treatment Iluvien, developed by Alimera Sciences, has obtained marketing authorization in Germany.

The decision, made by the Federal Ministry of Health of Germany, follows the successful completion of the Decentralized Regulatory Procedure (DCP). Iluvien was given a positive outcome from six Concerned Member States including Austria, France, Germany, Italy, Spain and Portugal.

The sustained release intravitreal implant delivers sub-microgram levels of fluocinolone acetonide for as long as 36 months. Latest clinical trials demonstrate that 38% of DME patients experienced an improvement in best-corrected visual acuity of 15 letters or more on the ETDRS chart.

Professor Albert Augustin, professor and chairman of the Department of Ophthalmology, Klinikum Karlsruhe, Germany, said, "Iluvien will be a timely and much needed addition to the German market. As the largest country in Europe with a growing incidence of diabetic macular oedema, it has more DME patients than any of the other six countries. The approval of ILUVIEN in Germany will have a significant impact for the many patients with this chronic, debilitating disease."

Dan Myers, president and CEO of Alimera Sciences, commented, "We are very pleased to receive German marketing authorization for Iluvien, our fifth of seven expected approvals in the European Union. Assuming the closing of our recently announced financing, we anticipate that we will launch Iluvien in Germany during the first quarter of 2013."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.